和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 04-17 16:08:14

13.670

+0.120

+0.89%

最高13.710	最低13.150	成交量149.70万
今开13.550	昨收13.550	日振幅4.13%
总市值92.14亿	流通市值92.14亿	总股本6.74亿
成交额2,015万	换手率0.22%	流通股本6.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":13.67,"timestamp":1776413294003,"preClose":13.55,"halted":0,"volume":1497000,"delay":0,"changeRate":0.008856088560885551,"floatShares":674000000,"shares":674000000,"eps":0.10172271597392014,"marketStatus":"休市中","change":0.12,"latestTime":"04-17 16:08:14","open":13.55,"high":13.71,"low":13.15,"amount":20152038,"amplitude":0.041328,"askPrice":13.68,"askSize":2000,"bidPrice":13.61,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":0.10466483292583538,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":7,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":13.55,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":1.1014269255504558,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2625942275","title":"和誉-B(02256)授出29万份购股权及29万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625942275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625942275?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:49","pubTimestamp":1775656146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司于2026年4月8日根据首次公开发售后购股权计划授出29万份购股权予公司的3名雇员，惟须待购股权承授人接纳方可作实。公司于2026年4月8日根据2019年股权激励计划授出29万份受限制股份单位予公司的3名雇员，惟须待受限制股份单位承授人接纳方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","BK1161","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","02256","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138700288","title":"和誉-B更新3月股份变动月报表，已发行股份增加1,200,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138700288","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138700288?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:37","pubTimestamp":1775119053,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年4月2日发布2026年3月股份变动月报表。报告显示，截至2026年3月31日，公司法定股本维持5,000,000,000股普通股，面值为每股0.00001美元，注册股本总额仍为50,000美元，未见变动。已发行股份方面，由于有1,200,000股普通股通过期权行使获发行，截至3月末，公司已发行股份由上月底的672,361,350股增至673,561,350股，库存股数量维持在7,744,000股不变，合计总股本681,305,350股。购回与注销方面，公司于2025年分别购回的1,485,000股与1,000,000股普通股，截至2026年3月31日尚未注销。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624540176","title":"智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540176?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:33","pubTimestamp":1775086385,"startTime":"0","endTime":"0","summary":"美国执行载人绕月任务火箭发射升空当地时间4月1日傍晚，美国航空航天局新一代登月火箭“太空发射系统”从佛罗里达州肯尼迪航天中心发射升空，执行“阿耳忒弥斯2号”载人绕月任务。这是美国自1972年以来首次载人飞向月球。据知情人士透露，这家卫星制造与火箭发射公司已以保密方式递交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06681","02256","BK4585","BK1141","LU1807302812.USD","300750","LU1960683339.HKD","BK1593","688796","LU1152091168.USD","BK1576","LU1008478684.HKD","BK1515","BK1600","LU0880133367.SGD","BK1610","LU0067412154.USD","LU1152091754.HKD","BK1161","00460","03759","02315","XOP","BK1194","03750","BK4570","01857","BK1191","BK4588","XLE","300759","BK1116","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624593383?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","EMA","LU2778985437.USD","02256","IE00B543WZ88.USD","LU2476274720.SGD","BK4081","BK4585","VXUS","IE00BPRC5H50.USD","LU2476274308.USD","LU2488822045.USD","BK1161","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112160524","title":"和誉-BFGFR4抑制剂依帕格雷替尼获EMA授予肝细胞癌孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1112160524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112160524?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:04","pubTimestamp":1775009054,"startTime":"0","endTime":"0","summary":"和誉生物制药宣布，其研发的FGFR4抑制剂依帕格雷替尼（Irpagratinib）已获得欧洲药品管理局（EMA）授予的孤儿药资格，用于治疗肝细胞癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2476274308.USD","LU2778985437.USD","02256","IE00BPRC5H50.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199542666","title":"和誉-B旗下Irpagratinib获EMA授予肝细胞癌孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1199542666","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199542666?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960353,"startTime":"0","endTime":"0","summary":"和誉-B宣布，其研发的创新药物Irpagratinib已获得欧洲药品管理局授予的孤儿药资格认定，适应症为肝细胞癌。孤儿药资格是EMA为鼓励针对罕见疾病创新疗法研发而设立的特殊认定。获得该资格的药物将在欧洲市场享受一系列政策支持，包括临床开发指导、上市后市场独占期等权益。此次认定标志着Irpagratinib在肝细胞癌治疗领域的临床价值获得国际监管机构认可。此次EMA的认定将加速其在欧洲市场的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","BK1161","LU2476274308.USD","02256","LU2778985437.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256)：FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格，用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623581546?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","IE00B5MMRT66.SGD","02256","LU2488822045.USD","LU2476274720.SGD","LU2476274308.USD","BK1161","BK4081","IE00B543WZ88.USD","EMA","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124008086","title":"和誉-BFgfr2/3抑制剂Absk061获FDA批准开展针对儿童软骨发育不全的新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1124008086","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124008086?lang=zh_cn&edition=full","pubTime":"2026-03-31 14:12","pubTimestamp":1774937535,"startTime":"0","endTime":"0","summary":"和誉-B（Abbisko Therapeutics）宣布，其研发的Fgfr2/3抑制剂Absk061已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准，将用于治疗儿童软骨发育不全（Achondroplasia）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU2476274720.SGD","LU2488822045.USD","IE00B543WZ88.USD","BK1161","LU2778985437.USD","IE00BPRC5H50.USD","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623933313","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061治疗儿童软骨发育不全的IND获FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2623933313","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623933313?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:33","pubTimestamp":1774863200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，本公司之附属公司上海和誉生物医药科技有限公司(“和誉医药”)宣布，其高选择性小分子FGFR2/3抑制剂ABSK061用于治疗软骨发育不全(“ACH”)儿童患者的新药临床试验申请(“IND”)已获得美国食品药品监督管理局(“FDA”)许可。结合此前FDA授予的罕见儿科疾病资格(“ RPDD”)与孤儿药资格(“ODD”)，该进展将助力和誉医药加快推进ABSK061 海外临床开发进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","BK1161","LU2476274720.SGD","BK4588","LU2778985437.USD","IE00BPRC5H50.USD","LU2476274308.USD","IND","LABU","LU2488822045.USD","02256","IE00B5MMRT66.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620299991","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061 获FDA授予孤儿药资格认定 用于治疗软骨发育不全","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299991","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620299991?lang=zh_cn&edition=full","pubTime":"2026-03-19 08:16","pubTimestamp":1773879410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR2/3抑制剂ABSK061已获得美国食品药品监督管理局授予的孤儿药资格认定，用于治疗软骨发育不全。这是ABSK061近期获得FDA授予罕见儿科疾病资格认定后，在其全球开发进程中的又一关键里程碑。ABSK061用于治疗软骨发育不全已获得FDA授予的RPD和ODD认定，II期临床试验正在推进中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4588","IE00B5MMRT66.SGD","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","IE00BPRC5H50.USD","BK4585","BK1161","IE00B543WZ88.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619481780","title":"和誉-B(02256)：依帕戈替尼联合靶免疗法一线治疗晚期肝细胞癌完成 II期临床首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619481780","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619481780?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:14","pubTimestamp":1773620062,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼联合标准疗法，已在针对晚期或不可切除肝细胞癌一线治疗的II期临床研究中完成首例患者给药。在2025年欧洲肿瘤内科学会胃肠道肿瘤大会上，和誉医药公布了依帕戈替尼联合阿替利珠单抗治疗HCC的II 期研究结果。除单药治疗之外，和誉医药同时在探索依帕戈替尼联合抗PD-L1抗体的II期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B(02256)：依帕戈替尼联合靶免疗法一线治疗晚期肝细胞癌完成 II期临床首例患者给药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","LU2778985437.USD","LU2476274308.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","BK1161","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618418695","title":"和誉-B盘中异动 早盘大幅下挫5.11%报12.070港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618418695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618418695?lang=zh_cn&edition=full","pubTime":"2026-03-12 11:05","pubTimestamp":1773284740,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘11时05分，和誉-B股票出现波动，股价大幅跳水5.11%。截至发稿，该股报12.070港元/股，成交量64.3万股，换手率0.10%，振幅5.50%。资金方面，该股资金流入198.867万港元，流出539.469万港元。和誉-B股票所在的生物技术行业中，整体跌幅为2.03%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。ABSK091 是一种分子靶向候选产品,也是 FGFR亚型 1、2和3的强效和选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312110540a6b995f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312110540a6b995f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","BK1161","LU2476274720.SGD","LU2778985437.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2488822045.USD","02256","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618186911","title":"每日卖空追踪 | 和誉-B 03月11日卖空量成交6.3万股，卖空比例为2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618186911","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618186911?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217829,"startTime":"0","endTime":"0","summary":"和誉-B北京时间03月11日，跌0.78%，卖空量成交6.3万股，较上一交易日减少75.49%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163354a460b692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163354a460b692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2476274308.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","BK1161","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618924186","title":"和誉-B03月11日主力净流出177.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924186","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924186?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:16","pubTimestamp":1773216962,"startTime":"0","endTime":"0","summary":"03月11日, 和誉-B股价跌0.78%，报收12.72元，成交金额3285.1万元，换手率0.38%，振幅5.69%，量比1.09。和誉-B今日主力资金净流出177.5万元，上一交易日主力净流入199.8万元。该股近5个交易日上涨16.33%，主力资金累计净流入4.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出205.0万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162138a460ac70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162138a460ac70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","LU2476274308.USD","02256","IE00B543WZ88.USD","LU2778985437.USD","BK1161","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618998304","title":"和誉-B(02256)：FGFR2/3抑制剂ABSK061获FDA授予罕见儿科疾病药物资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618998304","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618998304?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:14","pubTimestamp":1773188070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性、口服小分子FGFR2/3抑制剂ABSK061，已获得美国食品药品监督管理局授予用于治疗软骨发育不全的罕见儿科疾病药物资格认定。其口服给药方式在便捷性和治疗依从性方面具有显著优势，尤其对儿科患者而言，这使得ABSK061有望成为治疗儿童和青少年ACH患者的具有潜在价值的治疗候选药物。目前，ABSK061正在开展针对3-12岁儿童ACH患者的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2778985437.USD","LABU","IE00B543WZ88.USD","LU2488822045.USD","IE00BPRC5H50.USD","02256","BK4588","BK1161","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618985985","title":"港股异动 | 和誉-B(02256)再涨超9% 贝捷迈全球III期MANEUVER研究结果荣登《柳叶刀》","url":"https://stock-news.laohu8.com/highlight/detail?id=2618985985","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618985985?lang=zh_cn&edition=full","pubTime":"2026-03-10 13:36","pubTimestamp":1773121010,"startTime":"0","endTime":"0","summary":"和誉-B(02256)再涨超9%，截至发稿，涨8.76%，报12.91港元，成交额2199.69万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU2778985437.USD","VXUS","IE00B543WZ88.USD","BK4585","BK4588","02256","LU2488822045.USD","LU2476274720.SGD","III","LU2476274308.USD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103606349","title":"异动解读 | 利好出尽，和誉-B盘中大跌6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103606349","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103606349?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:37","pubTimestamp":1773020231,"startTime":"0","endTime":"0","summary":"和誉-B(02256)今日盘中股价大幅下挫6.14%，引发市场关注。消息面上，公司近期发布了其核心产品贝捷迈®(盐酸匹米替尼胶囊，ABSK021)全球III期MANEUVER研究的积极结果，该结果已于国际顶级医学期刊《柳叶刀》正式发表，标志着该创新疗法获得了重要的国际学术认可。然而，市场似乎对此利好采取了“卖出事实”的反应。分析认为，尽管该研究数据优异，显示药物在治疗腱鞘巨细胞瘤方面具有显著疗效和良好安全性，且其新药上市申请已获美国FDA受理，但在重大利好消息正式公布后，部分投资者选择获利了结，导致了股价的短期回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618692617","title":"和誉-B(02256)：《柳叶刀》(The Lancet)发布贝捷迈®全球III期MANEUVER研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692617","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618692617?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:03","pubTimestamp":1773014618,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其自主研发的新型、口服、高选择性且高效的小分子CSF-1R抑制剂贝捷迈®(盐酸匹米替尼胶囊，ABSK021)的全球多中心III期MANEUVER研究结果，于3月5日(西欧时间)正式发表于国际医学期刊《柳叶刀》 (The Lancet)1。此次发表标志着和誉医药这一创新疗法在临床研究质量、数据完整性及国际学术认可度方面取得了重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IE00B5MMRT66.SGD","BK4134","III","LU2476274308.USD","LU2476274720.SGD","IE00BPRC5H50.USD","02256","LU2778985437.USD","LU2488822045.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114090662","title":"和誉-B（02256）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114090662","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114090662?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:40","pubTimestamp":1772700043,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年3月5日发布截至2026年2月28日的股份变动月报。公告显示，公司本月无新增发行及注销，股本总体维持稳定。已发行股份及库存股份亦无变化。截至2月底，公司已发行股份总数为672,361,350股，库存股份为7,744,000股，合计680,105,350股，维持与上月相同。在股份期权与激励计划方面，公司2021年9月16日经股东大会批准的首次公开发售后购股权计划共授出9,764,758份期权，报告期内无新增发行或自库存股份转让。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617543239","title":"每日卖空追踪 | 和誉-B 03月05日卖空量成交7.8万股，卖空比例为3.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617543239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617543239?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699429,"startTime":"0","endTime":"0","summary":"和誉-B北京时间03月05日，涨2.9%，卖空量成交7.8万股，较上一交易日减少86.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163345a6a5d8d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163345a6a5d8d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU2476274720.SGD","IE00BPRC5H50.USD","BK1161","IE00B5MMRT66.SGD","LU2488822045.USD","LU2778985437.USD","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":0.0927},{"period":"3month","weight":-0.0572},{"period":"6month","weight":-0.1106},{"period":"1year","weight":0.9985},{"period":"ytd","weight":0.0507}],"compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.0255},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.0207}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.033777},{"month":4,"riseRate":0.4,"avgChangeRate":0.018105},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}